1. Epigenetics
    PI3K/Akt/mTOR
  2. AMPK

YLF-466D (Synonyms: C24)

Cat. No.: HY-15840 Purity: 99.16%
Data Sheet SDS Handling Instructions

YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

For research use only. We do not sell to patients.
YLF-466D Chemical Structure

YLF-466D Chemical Structure

CAS No. : 1273323-67-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 462 In-stock
5 mg USD 420 In-stock
10 mg USD 600 In-stock
50 mg USD 1800 In-stock
100 mg USD 2520 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    YLF-466D purchased from MCE. Usage Cited in: Eur J Pharmacol. 2015 Apr 22;760:81-87.

    YLF-466D induces VASP phosphorylation by activating AMPK. (A) Phosphorylation of VASP by YLF-466D (YLF) and (B) its prevention by AMPK inhibitors. WP is treated with CC, ara-A and YLF-466D. Phosphorylation of VASP at Ser239 and Ser157 are measured by immunoblotting with phospho-specific antibodies.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

    IC50 & Target

    AMPK[1]

    In Vitro

    YLF-466D is capable of inhibiting platelet aggregation by activating AMPK and its downstream eNOS-cGMP-PKG signaling axis. Treatment of isolated platelets with YLF-466D results in AMPK activation in a concentration-dependent manner in a range of 50-150 μM. Under the same experimental condition, YLF-466D effectively inhibits aggregation induced by platelet agonists including Thrombin, ADP and Collagen. Such AMPK activation and aggregation inhibition are abolished by pretreatment with the AMPK inhibitors compound (CC) and ara-A, indicating that antiaggregatory effect of YLF-466D is mediated by AMPK. YLF-466D induces an activation-dependente NOS phosphorylation at Ser1177, an elevation of cyclic nucleotides cGMP and cAMP, and subsequent phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at Ser239 and Ser157. All these events are prevented by CC and ara-A. In addition to isolated platelets, YLF-466D attenuates whole blood aggregation induced by collagen[1].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.1462 mL 10.7312 mL 21.4625 mL
    5 mM 0.4292 mL 2.1462 mL 4.2925 mL
    10 mM 0.2146 mL 1.0731 mL 2.1462 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay
    [1]

    Blood is collected from the abdominal aorta of ether anesthetized rats using 3.2% sodium citrate as an anticoagulant (sodium citrate:blood=1:9) and diluted with normal saline (1:1). Blood is incubated with YLF-466D for 3 min and aggregation is induced with 7.5 μg/mL Collagen. Aggregation is assessed by measuring the impedance change with a whole blood aggregometer[1].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    465.93

    Formula

    C₂₉H₂₀ClNO₃

    CAS No.

    1273323-67-3

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.16%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    YLF-466D
    Cat. No.:
    HY-15840
    Quantity: